The prognostic significance of trisomy 4 in acute myeloid leukaemia is dependent on age and additional abnormalities by Chilton, L. et al.
7Department of Medicine, Mayo Clinic, Rochester, MN, USA and
8Department of Hematology and Medical Oncology, Emory
University, Atlanta, GA, USA
E-mail: phari@mcw.edu
9These authors contributed equally to this work.
REFERENCES
1 Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL et al.
Increased risk of monoclonal gammopathy in ﬁrst-degree relatives of patients
with multiple myeloma or monoclonal gammopathy of undetermined sig-
niﬁcance. Blood 2009; 114: 785–790.
2 Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D et al. Risk of
monoclonal gammopathy of undetermined signiﬁcance (MGUS) and subsequent
multiple myeloma among African American and white veterans in the
United States. Blood 2006; 107: 904–906.
3 Wang JH, Reinherz EL. Structural basis of T cell recognition of peptides bound to
MHC molecules. Mol Immunol 2002; 38: 1039–1049.
4 Trowsdale J, Knight JC. Major histocompatibility complex genomics and human
disease. Annu Rev Genomics Hum Genet 2013; 14: 301–323.
5 Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Forsti A et al. Common
variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 inﬂuences multiple
myeloma risk. Nat Genet 2013; 45: 1221–1225.
6 Smedby KE, Foo JN, Skibola CF, Darabi H, Conde L, Hjalgrim H et al. GWAS of follicular
lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic
susceptibility with diffuse large B-cell lymphoma. PLoS Genet 2011; 7: e1001378.
7 Ludwig H, Mayr W. Genetic aspects of susceptibility to multiple myeloma. Blood
1982; 59: 1286–1291.
8 Gragert L, Fingerson S, Albrecht M, Maiers M, Kalaycio M, Hill BT. Fine-mapping of
HLA associations with chronic lymphocytic leukemia in US populations. Blood
2014; 124: 2657–2665.
9 Erlich H. HLA DNA typing: past, present, and future. Tissue Antigens 2012; 80: 1–11.
10 Gragert L, Madbouly A, Freeman J, Maiers M. Six-locus high resolution HLA
haplotype frequencies derived from mixed-resolution DNA typing for the entire
US donor registry. Human Immunol 2013; 74: 1313–1320.
11 Fabrigar LR, Wegener DT. Exploratory Factor Analysis (Understanding Statistics).
Oxford University Press, 2011.
12 Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and
powerful approach to multiple testing. J R Stat Soc Series B (Methodological) 1995;
57: 289–300.
13 Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE et al. Differential microRNA regulation
of HLA-C expression and its association with HIV control. Nature 2011; 472:
495–498.
14 Naumova E, Mihaylova A, Stoitchkov K, Ivanova M, Quin L, Toneva M. Genetic
polymorphism of NK receptors and their ligands in melanoma patients: pre-
valence of inhibitory over activating signals. Cancer Immunol Immunother 2005;
54: 172–178.
15 Alcoceba M, Sebastian E, Marin L, Balanzategui A, Sarasquete ME, Chillon MC et al.
HLA speciﬁcities are related to development and prognosis of diffuse large B-cell
lymphoma. Blood 2013; 122: 1448–1454.
16 Wang SS, Abdou AM, Morton LM, Thomas R, Cerhan JR, Gao X et al. Human
leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. Blood
2010; 115: 4820–4823.
17 Preuss KD, Pfreundschuh M, Fadle N, Regitz E, Raudies S, Murwaski N et al.
Hyperphosphorylation of autoantigenic targets of paraproteins is due to inacti-
vation of PP2A. Blood 2011; 118: 3340–3346.
18 Preuss KD, Pfreundschuh M, Weigert M, Fadle N, Regitz E, Kubuschok B.
Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor.
J Clin Invest 2015; 125: 2179.
19 Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar MV. Clonal
Immunoglobulin against Lysolipids in the Origin of Myeloma. N Engl J Med 2016;
374: 555–561.
20 Sarkar S, van Gelder M, Noort W, Xu Y, Rouschop KM, Groen R et al. Optimal
selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A.
Cancer Immunol Immunother 2015; 64: 951–963.
Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)
OPEN
The prognostic signiﬁcance of trisomy 4 in acute myeloid
leukaemia is dependent on age and additional abnormalities
Leukemia (2016) 30, 2264–2267; doi:10.1038/leu.2016.200
It is well recognised that cytogenetics is a key prognostic factor in
acute myeloid leukaemia (AML)1 and that trisomy 4 occurs as a
rare chromosomal abnormality (o1%).1–3 The additional chromo-
some 4 may be present as a sole abnormality or occur in
association with other chromosomal changes. To date the
prognostic signiﬁcance of trisomy 4 in AML is unclear, partly
due to its rarity. Here, we examined clinical and genetical
characteristics, remission rates and survival outcomes of 87
patients with AML and trisomy 4 to ascertain the prognostic
signiﬁcance of this abnormality.
Patients with trisomy 4 were identiﬁed among those recruited to
UK-based AML treatment trials (AML10, AML11, AML12, AML14,
AML15 and AML16) between May 1989 and October 2009.4–9
Median follow-up time for the cohort was 10.1 years (range 0.3–21.9
years). The Ethics Committee of each participating centre and R3
(Wales) approved these studies. Informed consent was obtained
from all patients in accordance with the Declaration of Helsinki.
Cytogenetic analysis of pre-treatment bone marrow or periph-
eral blood was performed locally, reviewed centrally by the
Leukaemia Research Cytogenetics Group and collated retrospec-
tively. Karyotypes were reported using the International System
for Human Cytogenetic Nomenclature (ISCN).10 Cases with trisomy
4 in addition to chromosomal abnormalities that we have
previously deﬁned as favourable and adverse risk1 were removed
in order to investigate the independent prognostic relevance of
trisomy 4 among the intermediate risk group. As we have
previously deﬁned cases with a complex karyotype based solely
on the number of chromosomal abnormalities as intermediate
risk,11 they were retained in the study.
To examine the effects of age, patients were divided into
three groups (1–16 years (paediatric), adults o60 years and adults
60+ years).
Survival analysis was performed on patients treated with
intensive curative intent. The comparator group comprised of
5003 patients with a normal karyotype, classiﬁed as intermediate
risk, treated on the same protocols. Complete remission (CR) was
deﬁned as a bone marrow aspirate with o5% leukaemic blasts
and evidence of regeneration of normal hematopoietic cells.
Overall survival (OS) was calculated from the date of entry onto
the trial, to death from any cause or the date of last follow-up. For
those patients who achieved CR, relapse-free survival was time
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from CR to ﬁrst event (relapse or death in CR); cumulative
incidence of relapse is the cumulative probability of relapse with
death in CR as a competing risk. OS/relapse-free survival/
cumulative incidence of relapse percentages are quoted at 5
years. Event-free survival was deﬁned as time from randomisation
to either relapse or death in CR for patients who achieved a
remission, censored at date last known to be alive in remission.
Patients not achieving remission were deemed to have an event
on day 1. Surviving patients were censored on 31 March 2010
(AML10/11/12/14), or 1 January 2014 (AML15/16), when follow-up
was complete for 95% of patients.
Survival rates were calculated and compared using the Kaplan–
Meier method, log-rank test and Cox regression. Multivariate
analyses were adjusted for additional factors: age (as continuous
variable), protocol (paediatric/young adult/older adult), white
blood cell count, secondary disease and performance status.
Effect sizes are given as odds or hazard ratios with 95% conﬁdence
intervals. Categorical data were compared using Χ2 and Mantel–
Haenszel tests, and continuous variables using the Wilcoxon rank-
sum test. All P-values were two-tailed. Analyses were performed
using Intercooled Stata 13.1 for Windows (Stata Corporation,
College Station, TX, USA) and SAS v9.3 (SAS Institute Inc., Cary,
NC, USA).
We identiﬁed 87 patients with trisomy 4, who were stratiﬁed as
intermediate risk. Trisomy 4 was the sole cytogenetic abnormality
in 35 cases (40%), while 18 (35%) had additional chromosomal
gains. Among the structural abnormalities found in the remaining
34 cases (39%), the only recurrent changes were abnormalities of
12p (n= 3). The ratio of males to females was 1:1.5 with a median
age of 51 years (range 1–83 years). There was no difference in
distribution by sex or age based on whether trisomy 4 was found
alone or in association with other abnormalities (P = 0.359 and
P= 0.904 respectively; Table 1).
There were no differences in demographics according to the
type of additional abnormalities, both among adults in both age
categories and paediatric patients (n= 10).
The majority of adult (82%) and all paediatric patients (100%)
with trisomy 4 achieved CR. OS was 35% at 5 years both in
patients with trisomy 4 and comparator group (adjusted HR 1.19
(0.91–1.57) P= 0.2). Survival appeared marginally reduced in
patients with trisomy 4 as the sole karyotypic change, but did
not reach signiﬁcance (OS adjusted HR 1.01 (95% CI 0.56–1.82)
P= 1.0 (Figure 1), event-free survival adjusted HR 1.11 (95% CI
0.85–1.45) P= 0.4) The survival effects of trisomy 4 alone or in
association with other abnormalities were not signiﬁcantly
different (Figure 1). Regardless of trisomy 4 status, patients 460
years had an overall worse prognosis than the paediatric cases.
There was no signiﬁcant interaction between protocol and the
effect of trisomy 4.
Relapse occurred in 22% of trisomy 4 patients (n= 19), with a
similar relapse rate of 54% at 5 years to the comparator group
(Figure 1e), regardless of whether trisomy 4 existed alone or
in association with other abnormalities (P= 0.473). Paediatric
patients with trisomy 4 were more likely to relapse than their age
speciﬁc comparator group (60% vs 37%, P = 0.06) with most
relapses occurring within the ﬁrst 12 months following diagnosis
(Figure 1f). Although there was an observed difference in OS for
the paediatric patients, it was not signiﬁcant (40% vs 63% NK,
P= 0.18). Older adults had an inferior outcome (5-year OS 7%460
years).
Trisomy 4 is a rare chromosomal abnormality in AML, occurring
at an incidence of o1%. Although its prognostic relevance has
been frequently debated,1–3 its association to outcome remains
unclear. This uncertainty is due partly to the rarity of trisomy 4 and
the restriction of studies to cases in which it occurred as an
isolated abnormality.1–3 Here, we present the largest cohort to
date, of 87 patients treated on sequential MRC-UK AML trials. As
well as cases with trisomy 4 as the sole abnormality, those with
additional chromosomal changes, classiﬁed as intermediate risk,
were included in the study. In support of this case selection, we
have recently shown that the subgroup of patients with trisomy 4
in association with the favourable risk abnormality, t(8;21)(q22;
q22), maintained a high 5-year OS of 74% (Standard Error 1.5%),
although an increased rate of relapse was observed compared
with those patients without trisomy 4.12 Similarly, we observed
that patients with adverse risk abnormalities maintained the same
poor outcome regardless of the presence of trisomy 4 (data not
shown). Thus we restricted this study to cases within the
intermediate risk group.
Table 1. Demographic and clinical details of patients with and
without trisomy 4
Trisomy 4 P-value
Sole abnormality
(%)
With additional
abnormalities
(%)
Total 35 (40) 52 (60)
Sex
Male 14 (40) 26 (50) 0.359
Female 21 (60) 26 (50)
Age
o2 — 2 (4) 0.7a
2–5 — 1 (2)
5–15 4 (11) 3 (6)
16–25 2 (6) 4 (8)
26–35 5 (14) 6 (12)
36–45 3 (9) 6 (12)
46–55 6 (17) 10 (19)
56–65 7 (20) 9 (17)
66+ 8 (23) 11 (21)
White Cell Count (x109/L)b
o50 21 (60) 44 (88) 0.04a
⩾ 50 14 (40) 6 (12)
FAB typec
M0 — 10 (19) 0.116
M1 10 (29) 8 (15)
M2 4 (11) 1 (2)
M3 — —
M4 4 (11) 4 (8)
M5 2 (6) 4 (8)
M6
M7
RAEBt 1 (3) —
Other 1 (2)
Intensive treatment 33 (94) 46 (88)
CR 85% 80% 0.6
Transplants given in CR1
Stem cell transplant 10 (36) 7 (10) 0.3
Allograft 9 (90) 4 (57)
Sibling 5 (46) 2 (50)
MUD 4 (54) 2 (50)
Autograft 1 (10) 2 (29)
Unknown 0 (0) 1 (14)
Relapse 9 (26) 10 (19) 0.473
Died 13 (37) 13 (25) 0.225
Complex
1–3 abns 35 (100) 22 (42) o0.0001
⩾ 4 abns — 30 (58)
Abbreviations: CR, complete remission; FAB, French-American-British
Classiﬁcation; MUD, matched unrelated donor. aWilcoxon rank-sum test.
bavailable for 85 patients (98%). cavailable for 55 patients (64%).
Letters to the Editor
2265
© 2016 Macmillan Publishers Limited, part of Springer Nature. Leukemia (2016) 2232 – 2279
Trisomy 4 often occurs as the sole cytogenetic change. However
it may also be a component of a hyperdiploid karyotype,11 or
associated with other structural abnormalities. We showed no
signiﬁcant difference in distribution or outcome based on these
potential classiﬁcations. Abnormalities of 12p were the only
recurrent structural changes identiﬁed. We and others have
previously described 12p aberrations to be a poor prognostic
marker in childhood AML.13,14
Although patients in this cohort were treated on a number of
trials, the regimens were similar and performed within the same
institutions, thus reducing treatment bias. In this study, the
outcome of trisomy 4 patients was compared with those with a
normal karyotype, classiﬁed as intermediate risk, treated on the
same protocols. Trisomy 4 patients responded well to induction
chemotherapy with the majority in all age groups achieving
remission. Their 5-year OS was intermediate, comparable to those
with a normal karyotype. Outcome was similar irrespective of
whether the trisomy occurred alone or in association with other
abnormalities. Age is a well-known prognostic factor in AML,1,8
also reﬂected in this cohort, in which older patients, notably
adults 460 years had an inferior outcome. Despite an initial
good response to treatment, patients with trisomy 4 were
susceptible to relapse. In adults the relapse rate was similar to
other patients with an intermediate risk proﬁle. However
paediatric patients with trisomy 4 had a signiﬁcantly
higher relapse rate than adults with the same abnormality,
occurring within the ﬁrst year following diagnosis. Although
patient numbers in this study were small, the increased rate
of relapse was signiﬁcant. As OS was not different from those
with a normal karyotype, these observations suggest that
trisomy 4 patients are being salvaged by relapse therapy.
It has previously been suggested that c-KIT mutations (located
to 4q12) may inﬂuence the function of trisomy 4 in
leukaemogenesis.2,3,15 Although mutation data were not available
for these patients, the impact would be insigniﬁcant, due to the
low reported incidence (10%) of c-KIT mutations in association
with trisomy 4 as the sole abnormality.2
This is the largest reported series of trisomy 4 in AML with
extensive follow-up data. Evidence from this study conﬁrms that
these patients belong to the intermediate risk group, by
comparison with patients with intermediate risk normal karyotype
AML. The conclusion is that paediatric patients should be closely
monitored for risk of relapse.
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Figure 1. Kaplan–Meier survival curves demonstrating OS for AML patients with trisomy 4 compared with patients with a normal karyotype
classiﬁed as intermediate risk.
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Concurrent PI3K and NF-κB activation drives B-cell
lymphomagenesis
Leukemia (2016) 30, 2267–2270; doi:10.1038/leu.2016.204
Aberrant activation of the PI3K and NF-κB pathways occurs
frequently in human B-cell lymphomas.1,2 Recent studies sug-
gested reciprocal molecular interactions between these two
pathways in lymphomagenesis. For example, PI3K inhibition
suppresses NF-κB activity in human Burkitt’s lymphoma and
diffuse large B-cell lymphoma,3,4 while blockade of NF-κB causes
suppression of PI3K activity in primary effusion lymphoma cell
lines.5 Despite frequent alterations and molecular interactions of
these two pathways in human lymphomas, genetic activation of
anyone of these two pathways was not sufﬁcient to initiate
lymphoma development in mice.6–8
We recently reported that mutant mice (termed miR-17 ~ 92
TG mice) with B-cell-speciﬁc transgenic expression of
miR-17 ~ 92, a cluster of six microRNAs (miRNAs) that are
frequently upregulated in human cancers,9–11 spontaneously
developed B-cell lymphomas with a high incidence.12 Subse-
quent molecular analyses showed that transgenic miR-17 ~ 92
expression led to constitutive activation of the PI3K and
canonical NF-κB pathways by suppressing the expression of
multiple negative regulators of these pathways.12 However, it
remains unclear whether functional cooperation of these two
pathways is sufﬁcient to drive lymphoma development and,
thereby, to mediate the lymphomagenic effect of miR-17 ~ 92
overexpression.
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